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ecognition of ligands by toll-like receptor (TLR) 2
requires interactions with other TLRs. TLRs form a
combinatorial repertoire to discriminate between the
diverse microbial ligands. Diversity results from extracellular
and intracellular interactions of different TLRs. This paper
demonstrates that TLR1 and TLR2 are required for ara-lipo-
arabinomannan– and tripalmitoyl cysteinyl lipopeptide–
stimulated cytokine secretion from mononuclear cells.
Confocal microscopy revealed that TLR1 and TLR2 co-
translationally form heterodimeric complexes on the cell
R
 
surface and in the cytosol. Simultaneous cross-linking
of both receptors resulted in ligand-independent signal
transduction. Using chimeric TLRs, we found that expression
of the extracellular domains along with simultaneous
expression of the intracellular domains of both TLRs was
necessary to achieve functional signaling. The domains from
each receptor did not need to be contained within a single
contiguous protein. Chimeric TLR analysis further deﬁned
the toll/IL-1R domains as the area of crucial intracellular
TLR1–TLR2 interaction.
 
Introduction
 
The toll-like receptor (TLR) family of proteins is an integral
part of the human innate immune system (Means et al.,
2000; Medzhitov and Janeway, 2000; Akira et al., 2001).
The function of the innate immune system is thought to
be the recognition of invading pathogens, the activation of
inflammation to control pathogen spread, and the subsequent
activation of an adaptive immune response specifically directed
to the elimination of the pathogen.
To date, at least 10 different human TLRs have been
identified (Means et al., 2000; Medzhitov and Janeway,
2000; Akira et al., 2001), and at least two additional mouse
TLRs are present in the GenBank/EMBL/DDBJ database.
Moreover, according to some authors, more TLRs will be
found in the future (Takeda et al., 2003). TLRs are expressed
on cells of the immune system, including monocytes,
macrophages, dendritic cells, and lymphocytes; however,
their expression is also observed in other cells, including
vascular endothelial cells, lung and intestinal epithelial cells,
cardiac myocytes, and adipocytes (Akira et al., 2001).
TLRs distinguish a great variety of microbial ligands,
including molecules conserved within the major groups of
pathogens such as Gram-positive and Gram-negative bacteria,
mycobacteria, spirochetes, viruses, and fungi (Means et al.,
2000; Akira et al., 2001).
All identified TLRs are type I transmembrane proteins.
Their extracellular domains contain leucine-rich repeats that
may participate in ligand recognition or act as structural
scaffolds for ligand recognition sites (Lien et al., 1999,
2000). The intracellular domains contain regions that are
highly homologous to the intracellular domain of the IL-1R,
and these regions are referred to as toll/IL-1R (TIR) domains
(Means et al., 2000; O’Neill, 2000; Akira et al., 2001). The
intracellular signaling pathway is known to activate mainly
the nuclear factor kappa B (NF
 
 
 
B) transcription factor
(Medzhitov et al., 1998; Muzio et al., 1998; Zhang et al.,
1999), which in turn triggers the expression of many pro-
inflammatory cytokines such as TNF-
 
 
 
, IL-1
 
 
 
, IL-6, and
IL-8 and leads to maturation of antigen-presenting cells
(Akira et al., 2001).
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One of the most studied TLRs, TLR2, has been shown to
recognize a wide array of microbial molecules (Aliprantis et
al., 1999; Brightbill et al., 1999; Lien et al., 1999; Means et
al., 1999a; Takeuchi et al., 1999; Underhill et al., 1999;
Yoshimura et al., 1999). For example, TLR2 participates in
recognition of Gram-positive bacteria, peptidoglycan, li-
popeptides, and zymosan from yeast cell wall; moreover, lep-
tospiral lipopolysaccharide (LPS) exerts its activity in a
TLR2-dependent manner (Werts et al., 2001). TLR2 is also
involved in recognition of viable 
 
Mycobacterium tuberculosis
 
as well as recognition of lipoarabinomannan from rapidly
growing mycobacteria (Means et al., 1999a,b). Moreover,
recent reports revealed numerous additional ligands recog-
nized via TLR2 (for review see Lien and Ingalls, 2002).
Recently, it has been shown that TLRs interact with other
different coreceptors as well as with each other (Ozinsky et al.,
2000; Wyllie et al., 2000; Akira et al., 2001; Hajjar et al., 2001;
Imler and Hoffmann, 2001; Takeuchi et al., 2001, 2002; Alex-
opoulou et al., 2002; Latz et al., 2002). TLR4 interacts with at
least two other proteins, CD14, MD-2 in the human macro-
phage, and human embryonic kidney 293 (HEK293) cell re-
sponse to LPS (Imler and Hoffmann, 2001; Latz et al., 2002).
In recent analyses of TLR1 and TLR2 knockout mice,
these receptors were shown to cooperate in recognizing 
 
Bor-
relia burgdorferi
 
 outer-surface protein A lipoprotein OspA
(Alexopoulou et al., 2002). Knockout experiments have also
suggested that TLR1 and TLR2 cooperate in the recognition
of the 19-kD mycobacterial lipopeptide and several syn-
thetic triacylated lipopeptides (Takeuchi et al., 2002).
In this report, we define the nature of TLR1 and TLR2 in-
teraction. Antibody cross-linking analyses suggest that cooper-
ation between TLR1 and TLR2 on the cell surface of normal
human peripheral blood mononuclear cells (PBMCs) leads to
the activation of pro-inflammatory cytokine secretion. Using
fluorescent protein–tagged TLR1 and TLR2, our confocal mi-
croscopy results indicate colocalization between TLR1 and
TLR2. In addition, we show that the simultaneous expression
of the extracellular and intracellular domains of both TLR1
and TLR2 is essential for ara-lipoarabinomannan (araLAM)
recognition. Thus, our analyses suggest that TLR1 and TLR2
associate functionally in a signaling complex.
 
Results
 
Anti-TLR1 and -TLR2 mAbs block cytokine production 
in PBMCs stimulated with AraLAM and tripalmitoyl 
cysteinyl lipopeptide (Pam
 
3
 
CSK
 
4
 
)
 
Genetic studies suggest that TLR2 is required for the recog-
nition of a diverse group of microbial ligands, including
araLAM, Pam
 
3
 
CSK
 
4
 
, and zymosan. The role of TLR1 and
Figure 1. Anti-TLR1 and -TLR2 mAbs 
block the IL-6 response of human PBMCs 
to araLAM and Pam3CSK4. Fresh human 
PBMCs were preincubated for 30 min 
with anti-TLR1 mAb (GD2.F4) or anti-
TLR2 mAb (11G7) before adding the 
stimulants. After 18 h of stimulation 
with 1  g/ml araLAM, 100 ng/ml 
Pam3CSK4 (A), 10  g/ml zymosan, or 
10 ng/ml phenol LPS (B), supernatants 
were harvested and IL-6 was measured 
by ELISA.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
 
Signaling via interaction of TLR1 and TLR2 |
 
 Sandor et al. 1101
 
TLR2 in the response of normal human PBMCs to these
ligands was analyzed in antibody-blocking experiments. Pre-
treatment of PBMCs with either anti-TLR1 or -TLR2
(11G7) antibodies blocked IL-6 cytokine production in re-
sponse to araLAM and Pam
 
3
 
CSK
 
4
 
 (Fig. 1 A). In contrast,
both antibodies failed to inhibit the IL-6 cytokine secretion
after stimulation with zymosan. Moreover, as expected, ad-
dition of anti-TLR1 or -TLR2 antibodies to PBMCs did not
exert any blocking effect to LPS stimulation (Fig. 1 B).
These results suggest that TLR1 and TLR2 both participate
in the response to araLAM and Pam
 
3
 
CSK
 
4
 
.
 
TLR1 cooperates with TLR2 on the cell surface 
to initiate signal activation: antibody 
cross-linking experiments
 
Both antibody-blocking experiments and TLR knockout an-
imal analyses suggest that TLR2 signaling involves coopera-
tion with other TLRs, particularly TLR1 and TLR6. Thus, a
functional signal transduction complex seems to require ele-
ments of both receptors. We hypothesized that cross-linking
TLR1 and TLR2 might mimic their engagement by a ligand
and thus activate signal transduction and cytokine secretion.
We analyzed the ability of plate-bound antibodies to TLRs
to activate normal human cells. PBMCs were incubated on
sterile tissue culture plates coated with mAbs to TLR1
(GD2.F4), TLR2 (2.1) alone, or in combination. We ob-
served that a combination of anti-TLR1 and -TLR2 specific
mAbs activated IL-8 secretion from PBMCs in a dose-
dependent manner. It should be noted that the aggregation
of TLRs by soluble antibodies did not activate these cells to
secrete cytokines, whereas the same anti-TLR antibodies did
activate cytokine secretion when they were prebound to tis-
sue culture plates upon which the TLR-expressing cells were
cultured. Individually, neither anti-TLR1, anti-TLR2, nor
isotype control antibodies alone were sufficient to elicit IL-8
secretion (Fig. 2).
 
TLR1 colocalizes with TLR2 inside and on 
the surface of cells
 
The antibody blocking and cross-linking experiments sug-
gested that TLR1 and TLR2 can associate in a functional
signaling complex. Therefore, we investigated the possible
interaction between TLR1 and TLR2 by confocal micros-
copy. HEK cells were stably transfected with TLR1 and
TLR2 tagged at their COOH termini with YFP or CFP.
This method of epitope tagging appears to have no effect on
TLR function (unpublished data; Latz et al., 2002).
Cells transfected with TLR2
 
YFP
 
 or TLR4
 
YFP
 
 fusion pro-
teins alone displayed a predominant membrane localization
of the receptors. In contrast, TLR1
 
YFP
 
-expressing cells dis-
played a diffuse pattern of TLR1 distribution (Fig. 3 A). Co-
transfection of cells with TLR1
 
YFP
 
 and TLR2
 
CFP
 
 fusion pro-
teins resulted in aggregation of TLR1 and TLR2 both on the
surface and inside the cells (Fig. 3 B). Antibody-induced ag-
gregation of TLR2 on the surface of the cells led to coaggre-
gation of TLR1 (Fig. 3 C), whereas antibody-induced sur-
face aggregation of MHC I did not coaggregate TLR1 or
TLR2 (Fig. 3 D). As a further control, we surface aggregated
TLR2 in TLR4
 
YFP
 
-expressing cells. Capping of TLR2 (Fig. 3
E, red) did not lead to coaggregation of TLR4 (Fig. 3 E,
green), indicating the specificity of the observed coaggrega-
tion of TLR2 and TLR1. These results suggest that TLR1
and TLR2 are preassembled into heteromultimeric com-
plexes on the cell surface.
 
Dominant-negative TLR2 and TLR1 inhibit response to 
araLAM and zymosan: loss of function analyses
 
HEK293 cells constitutively express a cytoplasmic pool of
TLR1 that can be detected by fluorescent staining analysis of
permeabilized cells and TLR1 mRNA-specific RT-PCR (un-
published data). Transfection of these cells with wild-type
TLR2 is sufficient to confer responsiveness to both araLAM
and zymosan (Kurt-Jones et al., 2002). To investigate the
role of TLR2 and TLR1 in response to araLAM and zymo-
san, various mutants of TLR2 and TLR1 proteins were gen-
erated. Based on a dominant-negative mutation of the TIR
domain of TLR4 found in the C3H/HeJ mice (Poltorak et
al., 1998; Hoshino et al., 1999), the corresponding homolo-
gous conserved proline within the TIR domain of TLR2 pro-
tein was mutated to histidine TLR2 P681H. A second TLR2
mutant was generated in which a stop codon was introduced
at aa 643, resulting in the deletion of the conserved intracel-
lular TIR domain TLR2
 
 
 
TIR. Co-transfection experiments
were performed using increasing amounts of TLR2 mutant
proteins with a constant amount of TLR2 wild-type protein.
The response of transfected cells to araLAM and zymosan
was determined. Transient transfection of HEK293 cells sta-
bly expressing CD14 on the surface (HEK293-CD14) with
increasing amounts of TLR2 mutants resulted in dose-
dependent impairment of NF
 
 
 
B activation in response to
both araLAM and zymosan (Fig. 4, A and B).
To analyze the role of TLR1, a cytoplasmic deletion mu-
tant (TLR1
 
 
 
cyt) was tested (Wyllie et al., 2000). In this
Figure 2. TLR1 cooperates with TLR2 on the cell surface to initiate 
IL-8 secretion. Control antibody (OKT8), anti-CD14 (26ic), anti-TLR1 
(GD2.F4), and anti-TLR2 (TL2.1) mAbs were immobilized on sterile 
high protein binding polystyrene 96-well plates from 0.2 to 0.8  g/ml 
concentration. After blocking and washing, 7   10
5 human PBMCs 
were added to the antibody-coated wells in the presence of 5  g/ml 
polymyxin B. After 18 h of incubation, supernatants were harvested 
and levels of IL-8 were measured by ELISA.T
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construct, the intracellular protein sequence was deleted im-
mediately after the transmembrane region, thus the TLR1
protein lacked the entire cytoplasmic domain (including the
TIR domain). This TLR1
 
 
 
cyt truncation construct, when
transfected together with TLR2 wild-type protein into HeLa
cells, has been shown to abrogate the response to 
 
Salmonella
minnesota
 
 LPS preparation (Wyllie et al., 2000). Transfec-
tion of HEK293-CD14 cells with increasing amounts of
TLR1
 
 
 
cyt truncation construct resulted in a dose-depen-
dent decrease in NF
 
 
 
B activation in response to both
araLAM and zymosan (Fig. 4 C). Thus, dominant-negative
forms of both TLR1 and TLR2 inhibit the NF
 
 
 
B response
to araLAM and zymosan.
 
Neither the extracellular domain nor the intracellular 
domain of TLR2 alone is sufficient to activate an NF
 
 
 
B-
dependent response to araLAM, Pam
 
3
 
CSK
 
4
 
, or zymosan
 
To further understand the role of TLR1 and TLR2 in ligand
recognition, various types of TLR chimeric (fusion) proteins
were generated by domain swapping of the extracellular and
intracellular domains of TLR1, TLR2, and TLR4. Chimeric
TLR proteins were transfected into HEK293-CD14 cells,
and the response of the cells to TLR ligands was determined.
The expression level of chimeric TLR protein constructs on
the cell surface was comparable to the wild-type TLR pro-
tein expression (unpublished data). Cells transfected with a
 
Figure 3.
 
Confocal imaging of live HEK cells expressing fluorescent 
protein–tagged TLR1, TLR2, and TLR4.
 
 (A) Confocal microscopy of 
HEK cells stably expressing TLR1
 
YFP
 
, TLR2
 
YFP
 
, or TLR4
 
YFP
 
. HEK cells 
stably expressing either TLR1
 
YFP
 
, TLR2
 
YFP
 
, or TLR4
 
YFP
 
 were grown on 
glass-bottom tissue culture dishes, and living cells were analyzed by 
confocal microscopy at 37
 
 
 
C without any manipulation. Shown are 
confocal sections in representative cells. (B) TLR1 colocalizes with 
TLR2 in resting HEK cells stably expressing both TLR1
 
YFP
 
 and 
TLR2
 
CFP
 
. HEK cells stably expressing both TLR1
 
YFP
 
 and TLR2
 
CFP
 
 were 
grown on glass-bottom tissue culture dishes, and living cells were 
analyzed as described in A. Left, Localization of TLR2; center, 
distribution of TLR1; right, overlay of the left and middle images. In 
these cells without any manipulation and without ligand stimulation, 
TLR1 colocalizes with TLR2 (arrows and arrowheads). Representative 
confocal sections of cells are shown. (C) Surface cross-linking of 
TLR2
 
CFP
 
 by antibody leads to coaggregation of TLR1
 
YFP
 
 on the cell 
surface. Double transfectants of TLR2
 
CFP
 
 and TLR1
 
YFP
 
 were surface 
stained with anti-TLR2 antibody (clone TL2.1), and further cross-linked 
with Alexa
 
®
 
 647–conjugated polyclonal rabbit anti–mouse antibody 
(2
 
 
 
 Ab
 
Alexa674
 
, shown in blue) on ice. After incubation for 10 min at 
37
 
 
 
C to induce capping, living cells were analyzed by confocal 
microscopy, and representative cells are shown. Left, distribution 
(green) and surface labeling of TLR2
 
CFP
 
 with anti-TLR2 
 
 
 
 2
 
 
 
 Ab
 
Alexa674
 
 
(blue); middle, TLR1
 
YFP
 
 distribution (red) and the overlay image of 
all three colors. The transmitted light image and the fluorescence 
intensities of a representative section of the overlay image is shown 
in the right panels. Surface cross-linking of TLR2
 
CFP
 
 by antibody 
(blue) induced coaggregation of TLR2
 
CFP
 
 and TLR1
 
YFP
 
. (D) Antibody-
induced capping of MHC I does not induce coaggregation with 
TLR2
 
CFP
 
 or TLR1
 
YFP
 
. HEK cells stably expressing TLR2
 
CFP
 
 and TLR1
 
YFP
 
 
were stained for MHC I using a mouse monoclonal anti-HLA I 
antibody, counterstained and processed as described in B. Distribution 
of TLR2
 
CFP
 
 (green) and surface labeling of MHC class I with anti-MHC
I 
 
 
 
 2
 
 
 
 Ab
 
Alexa674
 
 (blue) are shown in the left panels; the middle panels 
demonstrate TLR1
 
YFP
 
 localization (red) and the overlay of all three 
colors. The transmitted light image and fluorescence intensities of a 
representative section of the overlay image are displayed in the right 
panels. MHC I cross-linking (blue) does not co-patch either TLR2
 
CFP
 
 
or TLR1
 
YFP
 
. (E) Antibody-induced capping of TLR2 does not coag-
gregate TLR4. Stably transfected HEK-TLR4
 
YFP
 
 cells (green) were 
transiently transfected with TLR2. Antibody-induced capping of TLR2 
was induced by sequentially incubating the cells with anti-TLR2 
(clone TL2.1) and anti-mouse IgG (Alexa
 
®
 
 647 conjugated; red). 
Aggregation of TLR2 did not influence the expression pattern of TLR4.T
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TLR [2–1] chimeric protein (consisting of the extracellu-
lar domain of the TLR2 fused to the intracellular domain
of TLR1) did not respond to stimulation with araLAM,
Pam
 
3
 
CSK
 
4
 
, and zymosan. Similarly, the reciprocal construct
TLR [1–2] (with the extracellular domain of TLR1 fused to
the intracellular domain of TLR2) was not able to elicit a re-
sponse to any of these stimulants (Fig. 5, A and B). These re-
sults suggested that neither the extracellular domain of
Figure 4. TLR2 and TLR1 mutants inhibit NF B activation in HEK 293 cells in stimulation with araLAM and zymosan. (A) The response of 
HEK293-CD14 cells to araLAM and zymosan is inhibited by a single point mutated TLR2 construct, TLR2-P681H. HEK293-CD14 cells were 
cotransfected with 5 ng TLR2-WT DNA and increasing amounts of TLR2-P681H (from 5 to 200 ng DNA). After 6 h of stimulation with 1  g/ml 
araLAM and 10  g/ml zymosan, cells were lysed and NF B luciferase reporter gene activity was measured. IL-1  was used as a positive control. 
Luciferase activity is expressed in normalized RLU as the ratio of NF B-dependent firefly luciferase activity to NF B-independent renilla luciferase 
activity. Data shown are the mean   SD of triplicate wells. (B) The response of HEK293-CD14 cells to araLAM and zymosan is inhibited by 
expression of a TLR2 mutant missing the TIR domain TLR2- TIR. HEK293-CD14 cells were cotransfected with 5 ng TLR2-WT DNA and increasing 
amounts of TLR2- TIR (from 5 to 200 ng DNA). After 6 h of stimulation with 1  g/ml araLAM and 10  g/ml zymosan, cells were lysed and NF B 
luciferase reporter gene activity was measured. IL-1  was used as a positive control. (C) The response of HEK293-CD14 cells to araLAM and 
zymosan is inhibited by expression of a cytoplasmic deletion mutant of TLR1, TLR1- cyt. HEK293-CD14 cells were cotransfected with 5 ng 
TLR2-WT DNA and increasing amounts of TLR1- cyt (from 5 to 200 ng DNA). After 6 h of stimulation with 1  g/ml araLAM and 10  g/ml 
zymosan, cells were lysed and NF B luciferase reporter gene activity was measured. IL-1  was used as a positive control.T
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TLR2 nor the intracellular domain of TLR2 alone was suffi-
cient to confer signaling in response to tested ligands. Simi-
lar results were obtained using TLR [1–4], TLR [2–3], TLR
[4–1], and TLR [2–5] chimeric fusion proteins including
their combinations (Table I).
Both extracellular and intracellular domains of TLR1 
and TLR2 are required for signaling in response to 
araLAM or Pam3CSK4
Neither the TLR [1–2] nor the TLR [2–1] chimeric proteins
alone were sufficient to confer responsiveness to TLR2
ligands. Therefore, we examined the ability of combinations
of these chimeric fusion proteins to signal. HEK293-CD14
cells were cotransfected with TLR [1–2] and TLR [2–1]
fusion proteins, and the response of cells to araLAM,
Pam3CSK4, and zymosan was tested. This combination of
chimeric receptors was sufficient to confer responsiveness to
araLAM and Pam3CSK4. Interestingly, the combination of
TLR [1–2] and TLR [2–1] did not confer responsiveness to
zymosan (Fig. 6, A and B). These results suggest that both
intracellular and extracellular domains of TLR1 and TLR2
are required in recognition of araLAM and Pam3CSK4. We
hypothesize that within the intracellular domains of both re-
ceptors, dimerization of TIR domains is essential for subse-
quent signal activation.
To analyze the role of the intracellular domain in signal-
ing, another TLR fusion protein was generated (TLR [2–1
TIR]) in which the TIR domain of TLR2 was replaced with
Figure 5. Neither the intracellular nor the extracellular domain of TLR2 is sufficient to confer NF B signal activation. (A) HEK293-CD14 
cells were transfected with either TLR [1–2] or TLR [2–1] DNA encoding chimeric protein and wild-type TLR2 DNA. After 6 h of stimulation 
with 1  g/ml araLAM, 100 ng/ml Pam3CSK4, or 10  g/ml zymosan, cells were lysed and NF B luciferase reporter gene activity was measured. 
IL-1  was used as a positive control. (B) A schematic model of separate TLR1 and TLR2 chimeric protein transfection. With TLR1 endogenously 
expressed, transfection only of the intracellular portion of TLR2 (TLR [1–2]) does not confer responsiveness as a result of missing TLR2 
extracellular domain causing ligand recognition failure. Transfection with only the extracellular portion of TLR2 (TLR [2–1]) is not sufficient 
to confer responsiveness because the TLR1 intracellular domain lacks the TLR2 intracellular domain for effective initiation of signaling pathways. 
With TLR1 endogenously present, transfection of TLR2-WT protein confers responsiveness by providing both extra- and intracellular domains 
needed for ligand recognition and signal activation respectively.T
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the TIR domain of TLR1. Transfection with the TLR [2–1
TIR] construct alone did not confer responsiveness to
araLAM and zymosan (Table I). HEK293-CD14 cells co-
transfected with TLR [1–2] fusion protein and TLR [2–1
TIR] fusion protein were activated in response to araLAM
and Pam3CSK4, but not to zymosan (Fig. 7, A and B). These
data suggest that the heterodimerization of the TIR domains
of TLR1 and TLR2 is essential for the signaling in response
to some (but not all) TLR2 ligands (i.e., araLAM and
Pam3CSK4, but not zymosan).
Discussion
Together, our data support the hypothesis that optimal acti-
vation of cytokine secretion by TLRs involves TLR1 and
TLR2 clustering on the cell surface. Work by several authors
has suggested that an association between TLR1 and TLR2
was necessary for activation of cytokine secretion by certain
ligands. Experiments with knockout mice have confirmed a
requirement for both TLRs in the response to certain TLR2
ligands. By mAb blocking, we have demonstrated that both
TLR1 and TLR2 are required for extracellular recognition of
araLAM and Pam3CSK4. This dual requirement (for both
TLR1 and TLR2) is confirmed by transfection of cells with
dominant-negative mutants of either TLR1 or TLR2. Anti-
body cross-linking experiments demonstrated that aggrega-
tion of TLR1 and TLR2 into the same domain was suffi-
cient to induce signal transduction events independently of
ligand recognition. Interestingly, transfection of cells with
labeled TLRs demonstrated the surprising finding that
Table I. Transfection of HEK-CD14 cells with various types of TLR 
chimeric constructs
Transfected vectors araLAM Zymosan IL-1 
TLR [1-2] - -  
TLR [2-1] - -  
TLR [2-1 TIR] - -  
TLR [1-4] - -  
TLR [4-1] - -  
TLR [2-3] - -  
TLR [2-4] - -  
TLR [2-5] - -  
TLR [1-2]   TLR [2-1]   -  
TLR [1-2]   TLR [2-1 TIR]   -  
TLR [1-2]   TLR [2-3] - -  
TLR [1-2]   TLR [2-4] - -  
TLR [1-2]   TLR [2-5] - -  
Figure 6. NF B signal activation re-
quires both extracellular and intracellular 
domains of TLR1 and TLR2. (A) HEK293-
CD14 cells were cotransfected with TLR 
[1–2] and TLR [2–1] DNA encoding 
chimeric proteins or wild-type TLR2 
DNA. After 6 h of stimulation with 
1  g/ml araLAM, 100 ng/ml Pam3CSK4, 
or 10  g/ml zymosan, cells were lysed 
and NF B luciferase reporter gene activity 
was measured. IL-1  was used as a 
positive control. (B) A schematic model 
of cotransfection of TLR [1–2] and TLR 
[2–1] chimeric proteins. Co-transfection 
of both chimeric proteins confers re-
sponsiveness as a result of concomitant 
expression of both intracellular and 
extracellular domains of TLR1 and TLR2. 
With TLR1 endogenously present, 
transfection with TLR2-WT alone is 
sufficient to confer responsiveness.T
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TLR1 and TLR2 are associated before ligand stimulation or
cross-linking. Using confocal microscopy and expressing
TLR1 in one color and TLR2 in another, we found both re-
ceptors are expressed on the surface of dual receptor-trans-
fected cells and are in close association without ligand or an-
tibody cross-linking.
Overexpression of TLR1 in HEK cells produced a diffuse
pattern of distribution, TLR1 being mainly localized inside
the cells with a minimal cell membrane involvement. On the
other hand, expression of TLR2 resulted in a more promi-
nent cell membrane localization (Fig. 3 A). Overexpressing
TLR1 in a TLR2-positive cell line produced aggregation of
TLR1 and TLR2 inside the cells as well as in the cell mem-
brane (Fig. 3 B). A similar colocalization pattern was ob-
served in several cell clones expressing fluorescent protein–
labeled TLR1 and TLR2. TLR1 and TLR2 were present in a
preassembled complex, and as such, are transported to the
cell membrane. This interaction was independent of ligand,
and the data suggest that these receptors heterodimerize be-
fore expression on the cell surface, perhaps by a cotransla-
tional association of the two receptors. The morphologic re-
distribution of fluorescent TLR1 and TLR2 molecules in
the double-labeled cell line (HEK-TLR1
YFP    TLR2
CFP)
was also functionally reflected in 2–3-fold higher basal IL-8
cytokine level secretion when compared with cells trans-
fected with TLR1
YFP or TLR2
CFP alone. Similarly, an over-
expression of TLR4 has been observed to cause higher basal
NF B activation and cytokine production (Medzhitov et al.,
1997; Kurt-Jones et al., 2002). However, the levels of basal
cytokine secretion of TLR4 overexpressing HEK cells are
 5–10 times higher than the double-labeled cell lines used
in our experiments. Our confocal data are consistent with
the work of Ozinsky et al. (2000), where TLR2 and TLR1
were found to be expressed on the cell surface, and the work
of Takeuchi et al. (2002), where association of TLR1 and
TLR2 was demonstrated by coimmunoprecipitation experi-
ments, supporting the idea of ligand-independent associa-
tion of TLR1 and TLR2.
Experiments with chimeric proteins indicated that neither
expression of TLR1 nor expression of TLR2 on the surface
by itself was sufficient for cytokine induction by araLAM or
Pam3CSK4. The easiest explanation for this result is to pos-
tulate that araLAM and Pam3CSK4 must bind to the NH2-
terminal portions of both TLR1 and TLR2. Each TLR may
contribute to a combined ligand-binding site for araLAM
and Pam3CSK4. Interestingly, use of COOH-terminal chi-
meric proteins revealed that the COOH termini of both
TLR1 and TLR2 are necessary for ligand-mediated induc-
tion of cytokines. This result suggests that either TLR1 is as-
sociated with different signaling or adaptor proteins than
Figure 7. Heterologous expression of 
the extracellular domains of TLR1 and 
TLR2 together with heterologous ex-
pression of the TIR domains of TLR1 
and TLR2 is sufficient for NF B signal 
activation. (A) HEK293-CD14 cells were 
cotransfected with TLR [1–2] and TLR 
[2–1 TIR] DNA encoding chimeric pro-
teins or wild-type TLR2 DNA. After 6 h 
of stimulation with 1  g/ml araLAM, 100 
ng/ml Pam3CSK4, or 10  g/ml zymosan, 
cells were lysed and NF B luciferase 
reporter gene activity was measured. 
IL-1  was used as a positive control. 
(B) A schematic model of cotransfection 
of TLR [1–2] and TLR [2–1 TIR] chimeric 
proteins. Co-transfection of TLR [1–2] 
chimeric protein containing the entire 
intracellular domain of TLR2 (including 
the TIR domain) with the TLR [2–1 TIR] 
chimeric protein containing the TIR 
domain of TLR1, confers responsiveness. 
The transfected cells express the extra-
cellular domains of TLR1 and TLR2 
(ligand recognition) as well as both the 
TIR domains of TLR1 and TLR2 (signal 
transduction). With TLR1 endogenously 
present, transfection with TLR2-WT alone 
is sufficient to confer responsiveness.T
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TLR2, or that both proteins interact with one another, and
this interaction is required for the association of adaptor
molecules. Further experiments will be necessary to define
the different associated molecules, but these experiments un-
derscore the fact that (1) TLR1–TLR2 interactions occur
naturally without ligand binding; (2) certain ligands appear
to be able to bind to both TLR1 and TLR2 extracellularly;
and (3) intracellular interaction between TLR1 and TLR2 is
necessary, suggesting that different adaptor or signaling pro-
teins are associated with different TLRs.
Several recent analyses performed in knockout mice con-
firmed the cooperation of TLR2 with other TLRs, namely
TLR1 and TLR6 (Hajjar et al., 2001; Takeuchi et al., 2001,
2002; Alexopoulou et al., 2002). These analyses suggest that
both TLR1 and TLR2 are involved in recognition of a na-
tive mycobacterial peptide as well as several triacylated li-
popeptides, whereas coexpression of TLR2 and TLR6 is re-
quired for recognition of diacylated lipopeptides. In the
phylogenetic tree of human TLR2, TLR1, and TLR6 pro-
teins belong to so-called “TLR2 subfamily.” TLR1 and
TLR6 proteins share 69.3% overall homology, but the TIR
domains of these receptors share  90% identity. Moreover,
these proteins have similar genomic structures consisting of
one exon and are located in tandem in the same chromo-
some, 4p14 (Rock et al., 1998; Takeuchi et al., 1999). It is
hypothesized that they may be a product of an evolutionary
duplication (Takeda et al., 2003). This gives the rationale of
TLR1 and TLR6 having the capability to distinguish subtle
differences in lipopeptide recognition; TLR1 being responsi-
ble for recognition of triacylated peptides, and TLR6 being
responsible for recognition of diacylated peptides.
TLR2, on the other hand, has been shown to recognize a
large array of microbial ligands. We hypothesize that TLR2
may have multiple ligand-binding sites itself or when heter-
omerized to either TLR1 or TLR6. This hypothesis is sup-
ported by our blocking data with the 11G7 mAb and by our
analyses of chimeric receptor combinations. Anti-TLR2
(11G7) antibody blocked the cytokine production in stimu-
lation with araLAM and Pam3CSK4 (Fig. 1 A); however, this
antibody did not inhibit cytokine secretion induced by zy-
mosan (Fig. 1 B), despite the fact that several analyses clearly
indicate that zymosan signals in TLR2- and TLR6-depen-
dent fashion (Ozinsky et al., 2000). Thus, the 11G7 anti-
TLR2 may fail to block zymosan signaling because the
epitope recognized by 11G7 is involved in araLAM, but not
zymosan or to an epitope involved in TLR1–TLR2 het-
erodimer activation. Our blocking data parallel previously
published reports in which another type of anti-TLR2
(2393) mAb, but not an isotype control antibody, was able
to block synthetic bacterial lipopeptide (Pam3CSK4)–medi-
ated reactive oxygen species generation in peripheral blood
leukocytes (Aliprantis et al., 1999).
Our transfection experiments with chimeric fusion pro-
teins suggest that dimerization of both the extracellular and
the intracellular domains of TLR1 and TLR2 is essential in
response to either araLAM or Pam3CSK4. HEK293-CD14
cells express endogenous TLR1 (but not TLR2; unpublished
data). Therefore, transfection with wild-type TLR2 protein
alone confers responsiveness to araLAM, zymosan, or bacte-
rial lipopeptides (Kurt-Jones et al., 2002). Separate transfec-
tion with TLR [1–2] or TLR [2–1] chimeric fusion proteins
demonstrated that neither the extracellular domain of TLR2
nor the intracellular domain of TLR2 alone is sufficient to
confer responsiveness to araLAM and Pam3CSK4 (Fig. 5, A
and B). These data are consistent with previous experiments
using CD4-TLR1 or CD4-TLR2 fusion proteins, which
suggested that neither TLR2 homodimers nor TLR1 ho-
modimers were sufficient to initiate signaling (Ozinsky et
al., 2000). Our data are consistent with the hypothesis that
heteromers of both extracellular and intracellular domains of
TLR1 and TLR2 may be necessary for ligand-dependent sig-
nal activation. Thus, cells cotransfected with TLR [1–2]
plus TLR [2–1] chimeric constructs responded to araLAM
and Pam3CSK4 (Fig. 6 A). These cotransfectants simulta-
neously expressed the extracellular domains of TLR1 and
TLR2, as well as the intracellular domains of both TLR1
and TLR2 (Fig. 6 B). The data are consistent with recent re-
ports in knockout animals demonstrating that TLR1 pairs
with TLR2 in recognition of Pam3CSK4 and 19-kD myco-
bacterial lipoprotein (Takeuchi et al., 2002). Similarly, co-
operative interactions of TLR2 with another TLR (TLR6)
have been demonstrated. These reports suggest that a func-
tional interaction between TLR2 and TLR6 is required for
responses to group B streptococci (Henneke et al., 2002), di-
acylated lipopeptide MALP-2 isolated from Mycoplasma fer-
mentans (Takeuchi et al., 2001), and phenol-soluble modu-
lin (Hajjar et al., 2001). Our results are further consistent
with experiments using dominant-negative constructs that
demonstrated signaling in a TLR1- and TLR2-dependent
manner by bacterial products (Wyllie et al., 2000). Other re-
cently performed experiments suggest that TLR1 and TLR2
are required for B. burgdorferi outer-surface lipoprotein rec-
ognition (Alexopoulou et al., 2002). Together, our comple-
mentation experiments with TLR1 and TLR2 chimeric pro-
teins further support the hypothesis that multimerization of
various TLRs is required for recognition of distinct ligands.
In our loss of function experiments using various mutants
of TLR1 and TLR2, we noted that TLR2 constructs with
mutation or deletion of the TIR domain (TLR2 P681H and
TLR2 TIR) exhibited a dose-dependent impairment of
NF B activation in cells stimulated with either araLAM or
zymosan. Recent analyses found a similar effect of TLR2
dominant-negative mutant constructs on murine macro-
phages stimulated with peptidoglycan, zymosan, or triac-
ylated bacterial lipopeptide (Ozinsky et al., 2000). Because
all the mutations in our TLR2 mutant proteins involved the
intracellular TIR domain and an inhibition in response to all
tested stimulants was observed, we conclude that the TIR
domain of TLR2 is essential for signal transduction in re-
sponse to araLAM and zymosan. Thus, signaling by TLR2,
like TLR4, requires an intact TIR domain; however, unlike
TLR4, TLR2 cannot function as a homodimer, but may rely
on sequences within the TIR domain of TLR1 for signal ac-
tivation (Ozinsky et al., 2000).
Interestingly, inhibition of zymosan responses was ob-
served using a TLR1 cyt construct, although chimeric
TLR1 and TLR2 constructs did not cooperate in the re-
sponse to zymosan (compare Fig. 4 C with Fig. 6 A). Fur-
ther, knockout experiments suggest that zymosan responses
are dependent on TLR2–TLR6 interaction. This apparentT
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contradiction between the dominant-negative, chimeric re-
ceptor, and knockout experiments may be due to sequester-
ing of TLR2 by the TLR1 cyt construct. The TLR1 cyt
may form nonfunctional heterodimers with the TLR2 wild-
type receptor, thus preventing TLR2 from associating with
other TLRs such as TLR6, which is known to be involved in
zymosan signaling (Takeuchi et al., 2001).
Sequestration may also be involved in the impairment of
NF B activation noted at high levels of TLR mutant gene
expression. Thus, at high levels of TLR2 dominant-negative
expression, the response to IL-1  is impaired. Because
TLR2 signaling and IL-1  signaling are both dependent on
TIR domains, this global inhibition may reflect sequestra-
tion of common intracellular signaling molecules (i.e., MyD
88, IRAK-1, TRAF 6) activated in the TLR and IL-1  sig-
naling pathways. Experiments done by others have demon-
strated that using dominant-negative MyD88, IRAK-1,
IRAK-2, and TRAF6 inhibited IL-1 ,  and LPS induced
NF B activation (Burns et al., 1998; Zhang et al., 1999;
Equils et al., 2001).
We have identified araLAM as a specific ligand for TLR1–
TLR2. Our analyses indicate that both extracellular and in-
tracellular domains of TLR1 and TLR2 are required for
ligand recognition and subsequent ligand-induced signal ac-
tivation (Ozinsky et al., 2000; Takeuchi et al., 2000, 2001,
2002; Wyllie et al., 2000; Akira et al., 2001; Alexopoulou et
al., 2002). TLR1 and TLR2 are present on the cell surface as
a preassembled heterodimer. Together, our experiments in-
dicate that TLR1 and TLR2 colocalize and associate func-
tionally in a signaling complex, explaining the requirement
for both proteins for ligand recognition.
Materials and methods
DNA expression vectors
Human TLR2 and TLR4 cDNAs were obtained from Tularik. The TLR
cDNAs encoded Flag-epitope–tagged proteins and had been cloned into
the pFlag-CMV-1 vector. Chimeric TLR2–TLR1 (TLR [2–1]) and TLR1–
TLR2 (TLR [1–2]) constructs were generated by PCR as follows: An XhoI re-
striction site was added just upstream of Cys 577 of TLR1 and Cys 585 of
TLR2 and used for the domain swapping. Intracellular and extracellular
domains were PCR amplified using Pfu Turbo DNA polymerase (Strat-
agene) and cross-assembled into pBlueScript
® II KS( ) (Stratagene).
The transmembrane and cytoplasmic regions of TLR1 and TLR2 were
PCR amplified using primers as follows: T2cyto-5, 5 -GCGCCTCGAGTGT-
CACAGGACAGCACTGGTGTCTG-3 ; TLR2–3, 5 -CGCGGGTACCCTAG-
GACTTTATCGCAGCTCTCAG-3 ; T1cyto-5, 5 -GCGCCTCGAGTGCAA-
CATAACTCTGCTGATCGTCACC-3 ; and TLR1-3, 5 -CGCGGGTAC-
CCTATTTCTTTGCTTGCTCTGTCAGC-3 . The PCR products were di-
gested and cloned into the KpnI and XhoI sites of pBlueScript
® II KS ( )
(Stratagene).
A portion of the extracellular domain of TLR1 was PCR amplified us-
ing primers as follows: TL1-Bam, 5 -CTTTCATTAGGATCCTCCAGCTG-
GTTTG-3 ; and T1ex-3, 5 -GCGCCTCGAGTTCAGACATGTGAAAGTC-
CTTTAGTAGG-3 . The PCR product was digested with BamHI and XhoI
and cloned into the BamHI and XhoI sites of the pBlueScript
® vector al-
ready containing the cytoplasmic region of TLR2. This vector was then di-
gested with BamHI and KpnI (KpnI site was blunted with Klenow enzyme),
and the fragment containing the regions of TLR1 and TLR2 was inserted
into the BamHI and SmaI sites of pFlag-CMV-1 TLR1.II KS( ) (Stratagene).
A portion of the extracellular domain of TLR2 was PCR amplified us-
ing primers as follows: TL2-RV, 5 -CTAACATTGATATCAGTAAGAAT-
AGTTTTC-3 ; and T2ex-3, 5 -GCGCCTCGAGCACCGAGAGGCGGA-
CATCCTGAACC-3 . The PCR product was digested with EcoRV and XhoI
and cloned into the EcoRV and XhoI sites of the pBlueScript
® vector al-
ready containing the cytoplasmic region of TLR1. This vector was then di-
gested with EcoRV and KpnI (KpnI site was blunted with Klenow enzyme),
and the fragment containing the cytoplasmic region of TLR1 was inserted
into the EcoRV and SmaI sites of pFlag-CMV-1 TLR2.
To construct the vectors TLR [1–2 TIR] and TLR [2–1 TIR], the domain
swapping was done using a NsiI restriction site that is conserved in TLR1
and TLR2. pCMV-Flag TLR1 was cut with NotI and NsiI (NsiI partial diges-
tion), and the fragment of 1,917 bp was cloned into the NotI and NsiI sites
of the pBlueScript
® containing the cytoplasmic region of TLR2. The result-
ing plasmid was then cut with NotI and KpnI, and the fragment containing
TLR [1–2 TIR] was inserted into the NotI and KpnI sites of pFlag-CMV-1.
Similar strategy was used to construct the TLR [2–1 TIR] vector.
Stimulants
Yeast zymosan was purchased from Sigma-Aldrich. Mycobacterial
araLAM, purified from rapidly growing avirulent mycobacteria, was pro-
vided by Dr. John Belisle (Colorado State University, Fort Collins, CO) un-
der the National Institutes of Health, National Institute of Allergy and In-
fectious Diseases contract N01-AI-75320 entitled “Tuberculosis Research
Materials and Vaccine Testing.” Pam3CSK4 was obtained from EMC Micro-
collections. Rough LPS (Sigma-Aldrich) was phenol extracted and used at
10 ng/ml for stimulation assays. Recombinant human IL-1  was purchased
from R&D Systems, and used as a positive control for NF B activation.
In vitro stimulation of human PBMCs:
antibody-blocking experiments
Human PBMCs were isolated from peripheral blood using Lymphocyte
Separation Medium (Mediatech). PBMCs were cultured in RPMI 1640 me-
dium supplemented with 10% FCS (Atlanta Biologicals) in 24-well plates
at 10
6 cells/well. For blocking experiments, PBMCs were preincubated for
30 min at 37 C in 5% CO2 with anti-TLR1 (clone GD2.F4; eBiosciences),
or anti-TLR2 (clone 11G7) mAbs or isotype control antibody (eBio-
sciences) at 10  g/ml concentration/well before the addition of stimulants.
Culture supernatants were collected after an overnight incubation at 37 C
in 5% CO2. Secreted IL-6 levels were determined by ELISA according to
manufacturer’s instructions (OptEIA; BD Biosciences). Data are representa-
tive of at least three independent experiments.
Antibody cross-linking experiments
Anti-TLR1 (clone GD2.F4; eBiosciences), anti-TLR2 (clone TL2.1; a gift of
Dr. Egil Lien, University of Massachusetts Medical School, Worcester,
MA), or isotype control OKT8 (CRL-8014; American Type Culture Collec-
tion) mAbs were added to sterile high protein binding capacity 96-well
plates (Costar) at varying concentrations in PBS and incubated overnight at
4 C. The plates were washed three times with PBS and blocked with 10%
FCS (Atlanta Biologicals) in PBS for 2 h. 7   10
5 PBMCs in RPMI 1640
with 10% FCS were added to each well and incubated for 18 h at 37 C in
a 5% CO2 humidified incubator. Low endotoxin mAb preparations were
used in all experiments. As an additional control, polymyxin B (cat.#
P4932; Sigma-Aldrich) at a 5- g/ml concentration was added to the cul-
ture medium to neutralize potential endotoxin contamination. Superna-
tants were harvested and IL-8 levels were determined by ELISA according
to manufacturer’s instructions (BD Biosciences). The results shown are rep-
resentative of three independent experiments.
Confocal microscopy imaging experiments
Stable cell lines of HEK293 cells expressing the fluorescent protein TLR con-
structs were engineered as described previously (Latz et al., 2002). Confocal
microscopy was performed with living cells that were seeded on 35-mm
glass-bottom tissue culture dishes (MatTek Corp.) 24–48 h before examina-
tion. Images were taken with a confocal microscope (TCS SP2 AOBS; Leica)
equipped with an acousto-optical beamsplitter using version 2 of the Leica
Confocal Software, and the images were further processed with Adobe Pho-
toshop
® software, version 6 and 7. The cells were kept at 37 C during imag-
ing using a warm stage apparatus. CFP-tagged proteins were visualized using
the 458-nm argon laser line; for YFP, the 514-nm line of a 100-mW argon la-
ser was used. Alexa
® 647 was excited with a 2.5-mW helium/neon laser
emitting at 633 nm. Cells expressing CFP and YFP proteins were sequentially
scanned using only one laser line active per scan.
Antibody-patching experiments
For antibody-patching experiments, either stably transfected HEK cells
(TLR1-YFP/TLR2-CFP) or TLR4-YFP cells transiently transfected with
pcDNA3-TLR2 were grown on glass-bottom 35-mm tissue culture dishes
and washed twice with ice-cold HBSS/1% FBS. The cells were then incu-
bated with 5  g/ml anti-TLR2 (clone TLR 2.1) or anti–human HLA I (clone
W6/32HL, cat.# RDI-CBL139–1XP; Research Diagnostics, Inc.) antibody in
HBSS/1% FBS as primary antibodies on ice for 30 min. After two washesT
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with cold HBSS, the cells were counterstained with Alexa
® 647–conju-
gated goat anti–mouse secondary antibody (Molecular Probes, Inc.). After
washing, the cells were incubated in prewarmed complete growth me-
dium for 10 min at 37 C and immediately analyzed by confocal micros-
copy. Representative results of three independent experiments are shown.
Transfection and reporter gene assays in HEK 293-CD14 cells
HEK293 cells (CRL-1573; American Type Culture Collection) stably ex-
pressing human CD14 (HEK293-CD14) were cloned as described previ-
ously (Kurt-Jones et al., 2002). Transfections of HEK293-CD14 cells were
performed using GeneJuice
® Transfection Reagent (Novagen) according to
manufacturer’s instructions. The cells were plated to 96-well plates at
2.5   10
4/well and transfected 24 h later with a total of 0.3  g DNA per
well. The transfected DNA included 80 ng NF B-driven firefly luciferase
plasmid (pGL-3-Basic Vector, cat.# E1751; Promega) and 20 ng HSV-TK
promoter-driven renilla luciferase plasmid (phRL-TK Vector, cat.# E6241;
Promega) along with wild-type or chimeric TLR constructs cloned into in
pFlag-CMV-1 vector (cat.# E7273; Sigma-Aldrich). TLR plasmids were
transfected at concentrations ranging from 5 to 200 ng/well. Empty pFlag-
CMV-1 vector was used to bring up the total amount of transfected DNA to
0.3  g per well.
The transfected cells were incubated overnight at 37 C in 5% CO2 hu-
midified incubator and then stimulated for 6 h with 10  g/ml zymosan, 1
 g/ml araLAM, 100 ng/ml Pam3CSK4, or 100 ng/ml IL-1 . Cells were lysed
using 50  l Passive Lysis Buffer (cat.# E1941; Promega), and firefly lu-
ciferase activity was measured using Dual-Glo™ Luciferase Assay System
(cat.# E2940; Promega) according to the manufacturer’s instructions. Lu-
ciferase activity was calculated in RLU as a ratio of NF B-dependent firefly
luciferase activity to NF B-independent renilla luciferase activity. The re-
sults are shown as the mean   SD of triplicate wells, and are representa-
tive of three independent experiments.
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